Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock Position Increased by Northern Trust Corp

Northern Trust Corp boosted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 37.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 404,462 shares of the company's stock after purchasing an additional 110,345 shares during the quarter. Northern Trust Corp owned about 0.71% of Harmony Biosciences worth $13,918,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Hillsdale Investment Management Inc. raised its position in shares of Harmony Biosciences by 0.4% during the 4th quarter. Hillsdale Investment Management Inc. now owns 68,000 shares of the company's stock worth $2,340,000 after buying an additional 300 shares in the last quarter. O Shaughnessy Asset Management LLC raised its holdings in shares of Harmony Biosciences by 2.1% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company's stock worth $704,000 after purchasing an additional 420 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Harmony Biosciences by 28.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock worth $80,000 after purchasing an additional 519 shares in the last quarter. Aviva PLC raised its holdings in shares of Harmony Biosciences by 3.9% in the 4th quarter. Aviva PLC now owns 18,072 shares of the company's stock worth $622,000 after purchasing an additional 686 shares in the last quarter. Finally, New York State Teachers Retirement System raised its holdings in shares of Harmony Biosciences by 2.6% in the 4th quarter. New York State Teachers Retirement System now owns 31,693 shares of the company's stock worth $1,091,000 after purchasing an additional 809 shares in the last quarter. 86.23% of the stock is currently owned by institutional investors.

Harmony Biosciences Stock Performance

Shares of HRMY opened at $34.23 on Friday. The company's 50 day moving average price is $31.42 and its 200 day moving average price is $34.00. Harmony Biosciences Holdings, Inc. has a 52 week low of $26.47 and a 52 week high of $41.61. The company has a market capitalization of $1.97 billion, a PE ratio of 16.22, a PEG ratio of 0.47 and a beta of 0.82. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $184.73 million for the quarter, compared to the consensus estimate of $184.26 million. During the same period in the previous year, the firm posted $0.67 earnings per share. The firm's revenue was up 19.5% on a year-over-year basis. Research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HRMY has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 target price on the stock. Cantor Fitzgerald upgraded shares of Harmony Biosciences to a "strong-buy" rating in a report on Tuesday. Mizuho boosted their target price on shares of Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a report on Thursday. HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Finally, UBS Group dropped their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Monday, April 28th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $52.78.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.